Axsome Therapeutics, Inc. AXSM
Axsome Therapeutics, Inc. statistics & valuation
Market cap$12.4B
P / S19.5×
Net margin-28.7%
FCF margin-14.7%
Net cash$205.2M
Enterprise value USD$12.2B
Earnings yield EBIT/EV-1.4%
Return on capital-53.6%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -26.1% | -72.7% | -85.7% | -359.3% | — | — | — | — | — | — |
| Net margin | -28.7% | -74.5% | -88.4% | -374.0% | — | — | — | — | — | — |
| FCF margin | -14.7% | -33.4% | -53.8% | -234.3% | — | — | — | — | — | — |
| Return on assets | -26.6% | -50.5% | -40.7% | -56.5% | -148.5% | -55.3% | -31.0% | -201.3% | -81.4% | -71.2% |
| Return on equity | -207.5% | -503.8% | -125.3% | -170.8% | -834.3% | -90.4% | -38.2% | -3301.5% | -173.1% | -126.1% |
| Debt / equity | 1.33× | 3.17× | 0.93× | 0.86× | 3.14× | 0.42× | 0.10× | 3.86× | 0.40× | 0.44× |
| Current ratio | 1.55 | 2.11 | 3.63 | 2.54 | 3.75 | 7.85 | 9.00 | 1.41 | 2.90 | 5.30 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.